2. Signaling Pathways
  3. PROTAC
  4. LYTACs

LYTACs

Lysosome-targeting chimeras

LYTACs

Related Products

PDF 0.09 MB

Lysosome targeting chimera (LYTAC) degrades target proteins via lysosomal pathway rather than common proteasome pathway. LYTAC degrades target proteins by binding to asialoglycoprotein receptor on lysosomal through its asialoglycoprotein receptor ligand. Another side of LYTAC is usually an antibody so it can bind to target protein for degradation.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148476
    Tri-GalNAc-DBCO 2999748-27-3 99.97%
    Tri-GalNAc-DBCO is a synthetic ligand composed of three GalNAc units connected to DBCO. Tri-GalNAc-DBCO can act as a ligand for the sialic acid-degrading protein receptor (ASGPR), and can be coupled with targeting proteins or small molecules to form GalNAc-LYTACs. Tri-GalNAc-DBCO specifically binds to ASGPR and, through receptor-mediated endocytosis, guides the coupled molecules to lysosomes for degradation.
    Tri-GalNAc-DBCO
  • HY-147102
    tri-GalNAc biotin 3062597-46-7 99.78%
    tri-GalNAc biotin is a biotinylated ASGPR (Asialoglycoprotein receptor) ligand. tri-GalNAc biotin promotes cellular uptake of neutravidin (NA) via ASGPR. tri-GalNAc biotin delivers neutravidin to lysosomes for degradation. tri-GalNAc biotin can be used for research of LYsosome TArgeting Chimera (LYTAC).
    tri-GalNAc biotin
  • HY-150151A
    GalNac-siRNA negative control (21nt) 99.09%
    GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia.
    GalNac-siRNA negative control (21nt)
  • HY-139482
    tri-GalNAc-COOH 1953146-81-0 ≥99.0%
    tri-GalNAc-COOH is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research.
    tri-GalNAc-COOH
  • HY-145368B
    Tri-GalNAc(OAc)3-Perfluorophenyl
    Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl modified Tri-GalNAc(OAc)3 (HY-148118), a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation.Tri-GalNAc(OAc)3-Perfluorophenyl can be used for the study of liver metabolism.
    Tri-GalNAc(OAc)3-Perfluorophenyl
  • HY-171342
    Mal-C2-amide-C10-tri-GalNAc 2893765-20-1
    Mal-C2-amide-C10-tri-GalNAc (Compound 1226) is an asialoglycoprotein receptor (ASGPR) binding ligand fragment and a component of lysosome-targeted bifunctional molecules. Mal-C2-amide-C10-tri-GalNAc promotes the sequestration and degradation of extracellular target molecules in lysosomes. Mal-C2-amide-C10-tri-GalNAc is used in the research of autoimmune diseases.
    Mal-C2-amide-C10-tri-GalNAc
  • HY-183061
    MrTAC-8
    MrTAC-8, methylarginine-targeting chimera (MrTAC), is a BRD4 degrader with DC50 values of 46 nM in HeLa cells. MrTAC-8 recruits PRMT1, PRMT3, PRMT4, PRMT5, and PRMT7 to target proteins, inducing arginine methylation that triggers lysosomal degradation. MrTAC-8 degrades proteins across diverse subcellular localizations and independent of native proteolytic routes. MrTAC-8 can be used for the research of cervical cancer, glioblastoma.
    MrTAC-8
  • HY-182959
    Hsp70TAC PD-1 Degrader-2
    Hsp70TAC PD-1 Degrader-2 is a PD-L1 Hsp70TAC (Hsp70-targeting Chimeras) degrader with Kd values of 0.36 μM. Hsp70TAC PD-1 Degrader-2 forms a ternary complex with Hsp70 and PD-L1 to drive PD-L1 degradation. Hsp70TAC PD-1 Degrader-2 induces degradation of mature membrane-bound PD-L1 in an Hsp70-dependent manner and via caveolin-mediated endocytosis and lysosomal trafficking. Hsp70TAC PD-1 Degrader-2 accumulates preferentially in tumor cells with elevated Hsp70 expression for tumor-selective PD-L1 degradation. Hsp70TAC PD-1 Degrader-2 can be used for the research of cancer, such as breast invasive carcinoma, glioblastoma multiforme, diffuse large b-cell lymphoma. (Pink: PD-1/PD-L1 ligand (HY-19745A); Blue: Hsp70 ligand (HY-182979); Black: linker (HY-182982)).
    Hsp70TAC PD-1 Degrader-2
  • HY-148118A
    Tri-GalNAc(OAc)3 TFA 1159408-65-7 98.09%
    Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models.
    Tri-GalNAc(OAc)3 TFA
  • HY-148118
    Tri-GalNAc(OAc)3 1159408-64-6 98.09%
    Tri-GalNAc(OAc)3 is a trivalent N-acetylgalactosamine (tri-GalNAc) derivative, which can be used as a linker to synthesize LYTACs.
    Tri-GalNAc(OAc)3
  • HY-147354
    TriGalNAc CBz 186613-57-0 98.73%
    TriGalNAc CBz is a GalNAc derivative and tri-GalNAc is an asialoglycoprotein receptor (ASGPR) ligand. TriGalNAc CBz can be used for mRNA drug delivery as well as lysosomal targeted chimerism (LYTAC) studies.
    TriGalNAc CBz
  • HY-171910
    tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12) 3099288-71-5 99.46%
    tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12) is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research.
    tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12)
  • HY-179737
    ASGPR ligand-2 3062599-51-0
    ASGPR ligand-2 (Compound 366) is an asialoglycoprotein receptor (ASGPR) binder. ASGPR ligand-2 can be coupled with recognition elements of target proteins (such as antibodies or antigen-binding fragments), and through the endocytosis mediated by ASGPR, the target protein is delivered to the lysosomes of liver cells, promoting the degradation of the target protein. ASGPR ligand-2 can be used for the research of metabolic disease.
    ASGPR ligand-2
  • HY-153880
    KRAS degrader-1 2795275-59-9
    KRAS degrader-1 is a potent KRAS degrader. KRAS degrader-1 targets specific proteins for degradation via the autophagy-lysosomal degradation pathway. KRAS degrader-1 is suitable for use in cancer research. (Blue: KRAS G12C-IN-72 (HY-128414); Black: Linker (HY-175587); Pink: 5-Iodoindolin-2-one (HY-76986); Blue + Black: KRAS ligand-Linker Conjugate 7 (HY-175586)).
    KRAS degrader-1
  • HY-142885
    M-MoDE-A (2) 2378837-56-8
    M-MoDE-A (2) is a bifunctional small molecule that mediates the degradation of extracellular proteins through the asialoglycoprotein receptor (ASGPR).
    M-MoDE-A (2)
  • HY-142881
    D-MoDE-A (1) 2378837-67-1
    D-MoDE-A (1) is a bifunctional small molecule that mediates the degradation of extracellular proteins through the asialoglycoprotein receptor (ASGPR).
    D-MoDE-A (1)
  • HY-164396
    Allyl-mannose-6-phosphonate 3030990-46-3
    Allyl-mannose-6-phosphonate (M6Pn; Compound 6) is a stable analogue of mannose-6-phosphate (M6P). Allyl-mannose-6-phosphonate can be used to synthesize M6Pn-peptide conjugates and construct lysosome-targeting chimeras (LYTAC).
    Allyl-mannose-6-phosphonate
  • HY-181829
    Ctx-L3
    Ctx-L3 is a selective EGFR PTAC (PSMA-targeted chimera) degrader (DC50: 4.3 pM in LNCaP cells) and LYTAC. Ctx-L3 recruits prostate-specific membrane antigen (PSMA) and mediates lysosomal degradation of EGFR in PSMA-positive prostate cancer cells. Ctx-L3 exhibits degrading activity against EGFR in prostate cancer cells. Ctx-L3 is applicable to related research on prostate cancer.
    Ctx-L3
  • HY-181830
    Atz-L5
    Atz-L5 is a PD-L1 PTAC (PSMA-targeted chimera) degrader (DC50: 18 pM in PC3-PIP cells; 2 pM in LNCaP cells) and LYTAC. Atz-L5 promotes lysosomal degradation of PD-L1 in PSMA-positive prostate cancer cells. Atz-L5 is applicable to the research of prostate cancer.
    Atz-L5
  • HY-174468
    dPDL1-4
    dPDL1-4 is a potent and selective eHSPTAC eHSP90 PD-L1 degrader with DC50s of 7.77 μM and 6.52 μM in HeLa and B16F10 cells. dPDL1-4 bridges eHSP90 with the target protein, inducing lysosomal degradation. dPDL1-4 can degrade PD-L1 significantly and inhibits tumor growth. dPDL1-4 can be used for the study of cervical cancer and melanoma. ((Pink: eHSP90 ligand (HY-174476); Blue: PD-L1 ligand (HY-116274); Black: Linker (HY-W021787); HSP ligand + linker: HY-174799)).
    dPDL1-4
Cat. No. Product Name / Synonyms Application Reactivity